Clinical Trial Search

Primary: Multiple Dose: Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24) of Talazoparib — 94.88; 106.5; 135.7; 249.8 nanogram*hour per milliliter

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 2; 1 Participants

Primary: Area Under the Concentration Time Cure From Time 0 to Last Quantifiable Concentration (AUC0-t) — 144500; 151600; 154600 h*µg/mL

Primary: Maximum Tolerated Dose — 21 Gray (Gy)

Primary: Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream…

Primary: AUC0-t — 37440.71; 34483.73; 41150.49 mUI*h/mL

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27 — 0.22; 0.22 hour

Primary: Detectable Plasma Concentrations of Diacerein and Rhein — 3; 2; 0; 0 Participants

Primary: Number of Participants With Smoking Abstinence at 6 Months — 6; 3 Participants

Primary: Observed Phototoxicity — 0.15; 0.15; 0.00; 0.00 Score on a scale — p=1.0000

Primary: Dose-Escalation Phase: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 Participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants